Introduction and Objective: The 78-week QWINT-3 trial assessed once-weekly efsitora (n=655) vs once-daily degludec (n=331) in adults with T2D currently on basal insulin. Here, we report the patient reported outcomes (PRO) findings at week 26 (primary timepoint).Methods: TRIM-D assessed 5 domains at baseline and week 26: treatment burden, daily life, diabetes management, compliance and psychological health, including total score. Higher scores indicate a better health state. The DTSQc assessed treatment (tx) satisfaction; SIM-Q evaluated tx complexity; BIE assessed the likelihood of incorporating a study insulin into a participant’s tx routine.Results: All 5 TRIM-D domains had improved scores with greater improvement for efsitora vs degludec at week 26 (Figure). More participants rated efsitora as “very simple” (46%) vs degludec (35%) (p<0.001) on SIM-Q, and “very likely” to incorporate it into their tx routine (efsitora 62% vs degludec 43%; p<0.001) on BIE. DTSQc indicated greater satisfaction score with efsitora (14.9) vs degludec (12.3) (p<.001).Conclusion: Treatment with weekly efsitora resulted in greater tx satisfaction, better overall health state, and reduced tx burden vs degludec in adults with T2D currently treated with basal insulin. Greater satisfaction and perceived improved overall health state may improve adherence and clinical outcomes.
R.M. Bergenstal: Advisory Panel; Abbott. Research Support; Abbott. Consultant; Abbott. Research Support; Dexcom, Inc. Consultant; Dexcom, Inc., Eli Lilly and Company. Research Support; Eli Lilly and Company. Consultant; Novo Nordisk. Research Support; Novo Nordisk. Consultant; Roche Diabetes Care, Sanofi, Medtronic. Research Support; Medtronic, Insulet Corporation, Hemsley Charitable Trust. Other Relationship; MannKind Corporation. Consultant; Medscape. Research Support; National Institute of Diabetes and Digestive and Kidney Diseases, Tandem Diabetes Care, Inc, UnitedHealth Group. Consultant; Vertex Pharmaceuticals Incorporated, Ascensia Diabetes Care, American Diabetes Association, Hygieia, embecta, Senseonics, Zealand Pharma A/S. A. Philis-Tsimikas: Advisory Panel; Dexcom, Inc. Research Support; Dexcom, Inc. Advisory Panel; Lilly Diabetes. Research Support; Lilly Diabetes. Advisory Panel; Novo Nordisk. Research Support; Novo Nordisk. Advisory Panel; Medtronic, Sanofi. H.W. Rodbard: Consultant; Bayer Pharmaceuticals, Inc. Research Support; Novo Nordisk, Lilly USA LLC. Speaker’s Bureau; Lilly USA LLC. Consultant; Endogenex, Kriya Therapeutics. Research Support; Inversago Pharma. S. Gangi: Research Support; Lilly USA LLC. Speaker’s Bureau; Lilly USA LLC. Research Support; Abbott Diagnostics, Amgen Inc, Ionis Pharmaceuticals. R.J. Threlkeld: Employee; Eli Lilly and Company. J. Mitra: None. L. Ilag: Employee; Eli Lilly and Company. Stock/Shareholder; Eli Lilly and Company. M.B. Davidson: Employee; Eli Lilly and Company. K. Syring: Employee; Eli Lilly and Company. Stock/Shareholder; Eli Lilly and Company. F. Gelsey: Employee; Eli Lilly and Company. Stock/Shareholder; Eli Lilly and Company.
Source link
Leave a Reply